Valuation: Glaukos Corporation

Market Cap 9.83B 8.53B 7.94B 7.29B 13.78B 938B 14B 93.47B 36.7B 467B 36.91B 36.1B 1,547B P/E 2026 *
-206x
P/E 2027 * 568x
Enterprise Value 9.65B 8.37B 7.79B 7.16B 13.53B 921B 13.75B 91.81B 36.05B 459B 36.25B 35.46B 1,520B EV / Sales 2026 *
14x
EV / Sales 2027 * 11.4x
Free-Float
96.35%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week+8.56%
1 month+19.29%
3 months+16.04%
6 months+39.65%
Current year+47.66%
1 week 145.78
Extreme 145.7759
184
1 month 136.18
Extreme 136.18
184
Current year 93.96
Extreme 93.96
184
1 year 73.16
Extreme 73.16
184
3 years 59.22
Extreme 59.22
184
5 years 33.33
Extreme 33.33
184
10 years 23.08
Extreme 23.075
184
Manager TitleAgeSince
Chief Executive Officer 65 2000-12-31
Director of Finance/CFO 56 2022-03-31
President 50 2022-03-31
Director TitleAgeSince
Chairman 65 2021-12-30
Director/Board Member 71 2014-06-30
Director/Board Member 57 2014-06-30
Date Insider Type Main position Quantity % Market Cap.
7/16/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
7/9/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
7/6/26 Fiscal year

Chief Financial Officer

30,000 0.0523%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%+8.56%+93.66%+116.13% 9.83B
-6.42%-1.38%-17.07%+14.92% 125B
-2.48%+1.62%-0.34%-2.24% 13.12B
+1.11%+10.55%-41.05%-67.95% 4.86B
-2.28%-0.67%-2.39%+35.25% 2.61B
-0.51%+7.84%+8.77%-54.38% 1.68B
+0.60%+5.00%-15.24%-21.40% 1.67B
+1.24%+5.88%-22.03%-30.49% 1.68B
+0.38%+2.07%-59.68%-82.55% 1.45B
Average -1.05%+2.94%-6.15%-10.30% 17.97B
Weighted average by Cap. -5.21%-0.16%-9.61%+15.08%

Financials

2026 *2027 *
Net sales 691M 599M 558M 512M 968M 65.89B 984M 6.57B 2.58B 32.81B 2.59B 2.54B 109B 842M 730M 680M 625M 1.18B 80.31B 1.2B 8.01B 3.14B 40B 3.16B 3.09B 133B
Net income -51.88M -45.01M -41.89M -38.49M -72.72M -4.95B -73.9M -493M -194M -2.46B -195M -191M -8.17B 18.93M 16.42M 15.28M 14.04M 26.53M 1.81B 26.96M 180M 70.67M 899M 71.07M 69.51M 2.98B
Net Debt -175M -152M -141M -130M -245M -16.68B -249M -1.66B -653M -8.31B -657M -642M -27.53B -273M -237M -220M -202M -382M -26.03B -389M -2.59B -1.02B -12.96B -1.02B -1B -42.94B
Logo Glaukos Corporation
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others.
Employees
1,094
Date Price Change Volume
26-07-31 US$166.72 -1.07% 1,032,220
26-07-30 US$168.52 +4.24% 2,559,596
26-07-29 US$161.66 +6.83% 3,137,806
26-07-28 US$151.33 -0.38% 1,144,674
26-07-27 US$151.91 -1.09% 727,532
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
166.72USD
Average target price
193.62USD
Spread / Average Target
+16.13%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GKOS Stock